[Duodenal gastrointestinal stromal tumor (GIST) with deletion in exon 11 of c-kit treated with emergency pancreaticoduodenectomy due to massive bleeding: a case report].

A Japanese woman in her 50s presented with coffee-ground vomiting at a local clinic and was referred to our hospital for further investigation. Esophagogastroduodenoscopy demonstrated a submucosal tumor in the descending part of the duodenum, and she was diagnosed with a gastrointestinal stromal tumor (GIST) by other imaging studies. Elective surgery of the tumor was initially planned. However, on the 13th day of hospitalization, emergency pancreaticoduodenectomy was performed because of massive hematemesis with hemorrhagic shock. Genetic analysis demonstrated a deletion in exon 11 of the c-kit gene, which could dramatically alter the clinical course. Although duodenal GIST with active bleeding is comparatively rare, we have to assume that it is the cause of gastrointestinal bleeding and treat such cases with a minimally invasive surgical procedure and neoadjuvant/adjuvant chemotherapy. It is necessary to accumulate more cases with duodenal GIST to establish an evidence-based therapeutic strategy.

[1]  Ji Li,et al.  Duodenal gastrointestinal stromal tumor: clinicopathological characteristics, surgical outcomes, long term survival and predictors for adverse outcomes. , 2013, American journal of surgery.

[2]  J. Blay,et al.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[3]  C. Raut,et al.  Clinical, Pathological and Surgical Characteristics of Duodenal Gastrointestinal Stromal Tumor and Their Influence on Survival: A Multi-Center Study , 2012, Annals of Surgical Oncology.

[4]  Aki Vehtari,et al.  One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.

[5]  亘 高山,et al.  選択的血管造影塞栓術施行後,待機的に膵頭十二指腸切除術を施行した出血性十二指腸gastrointestinal stromal tumorの1例 , 2012 .

[6]  C. Ferreira,et al.  Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors. , 2010, Anticancer research.

[7]  T. Tsujinaka,et al.  Survival Analysis of Patients With Duodenal Gastrointestinal Stromal Tumors , 2010, Journal of clinical gastroenterology.

[8]  C. Antonescu,et al.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[9]  M. Heinrich,et al.  Gastrointestinal stromal tumour , 2007, The Lancet.

[10]  J. Desai,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[11]  H. Joensuu,et al.  Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. , 2006, Gastroenterology.

[12]  R. Roskoski Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor. , 2005, Biochemical and biophysical research communications.

[13]  Adrian A Canutescu,et al.  Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling , 2005, Clinical Cancer Research.

[14]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Gaffney,et al.  Gastrointestinal stromal tumours , 2003, The British journal of surgery.

[16]  S. Hirota,et al.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.

[17]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[18]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[19]  哲章 亀山,et al.  腹腔鏡下十二指腸局所切除術を施行した十二指腸gastrointestinal stromal tumorの1例 , 2009 .

[20]  G. Demetri,et al.  Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665 , 2009, Journal of surgical oncology.

[21]  P. Loehrer Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications Through Protein Modeling , 2006 .